

The role of apoptosis in autoantibody production

Il ruolo dell'apoptosi nella produzione di autoanticorpi

R. Herrera-Esparza, D. Herrera-van-Oostdam, E. López-Robles, E. Avalos-Díaz

*Department of Immunology, Centro de Biología Experimental,
Universidad Autónoma de Zacatecas, Guadalupe, Zacatecas, México*

RIASSUNTO

L'apoptosi è un processo fisiologico che garantisce il ricambio cellulare; dopo l'apoptosi i residui cellulari vengono rimossi per fagocitosi. È stato dimostrato che l'alterazione di alcuni meccanismi coinvolti nell'apoptosi possono favorire l'autoimmunità. Ad esempio, un difetto nei meccanismi regolati da Fas in corso dell'ontogenesi linfatica può consentire la sopravvivenza di cloni autoimmuni; allo stesso modo, la mancata rimozione dei corpi apoptotici contenenti autoantigeni può attivare cloni autoreattivi preesistenti e risultare nella produzione di autoanticorpi.

Reumatismo, 2007; 59(2):87-99

In normal conditions, the intracellular autoantigens reach the cell surface by apoptosis and are normally cleared by phagocytes without inflammation, nevertheless the lack of depuration of apoptotic material foster the autoantibody production in individuals genetically predisposed, equally defects in signaling, execution and malfunction of the apoptotic pathways may induce autoimmunity, in consequence apoptosis is another way of understanding the autoimmunity (1).

Origins of autoantibodies

Autoantibodies may be expressed early during B cell ontogeny; nevertheless the autoimmune B cells are controlled by two check points: One in the bone marrow, this take place before the B cell maturation, in this check point the autoimmune clones are eliminated by receptor cross-linking. Another check point take place in the periphery and the autoimmune clones are eliminated by neglect (2).

Genetic mechanisms

The rearrangements of immunoglobulin genes produce a high affinity immune response, that is similar in normal and autoimmune individuals;

nevertheless in autoimmunity has been reported an abnormal gene rearrangement encoded by an atypical reading frames of CDR3, such rearrangement produce segments enriched in arginine that result in autoantibodies such as anti-dsDNA (3). Autoantibody production mainly results of hypermutation, this mechanism is normally expressed as response against mutant pathogens and produce a huge number of immune receptors against an unlimited number of antigens; the hypermutation is also important in vaccination (4). In spite that autoimmune B cells are usually deleted in bone marrow, few B cells can be transformed in auto-reactive cells in the periphery by somatic hypermutation, that is the case of the residue in 35 position of the H chain, this switch the affinity of the anti-phosphorylcholine to anti-dsDNA antibody (5). In consequence the bacterial and viral infections may induce somatic hypermutations of the V genes and produce cross reactivity against self-antigens; this has been reported in patients with SLE (6, 7).

Epitope spreading

T or B cells can recognize new epitops from an original antigenic site without cross reactivity with the same or different molecules; this ability is called epitope spreading. In SLE the response against Sm ribonucleoprotein is a good example of sequential progression in epitope recognition, therefore the anti-Sm B/B' response is compro-

Indirizzo per la corrispondenza:

Rafael Herrera-Esparza, MD
Chepinque 306, Col. Lomas de la Soledad,
Zacatecas 98040, México
E-mail: herrerar@uaz.edu.mx

mised with the first epitome and its close relative (second epitome enlarged by neighbor amino acids) which is also recognized by the same antibody, the third or fourth epitomes are also recognized by the same mechanism, in consequence different epitops from a unique antigenic structure can be recognized by a single antibody (8). In diabetes the anti-GAD65 and anti-IA2 antibodies are linked to epitope spreading. In endemic pemphigus foliaceus, autoantibodies against the ectodomain 5 of the COOH end of desmoglein 1 appear firstly in the preclinical phase of the disease, then by epitope spreading autoantibodies against the ectodomain 1 (residues 1-108) and 2 (109-221) of the NH3 end are produced and coincide with the clinical manifestations (9).

Pos-translational modification of epitopes

A steric modification of a protein may trigger autoantibodies; this is the case of the peptides that are citrullinated like the Sa antigen, which is specific of rheumatoid arthritis (RA). Sa is a citrullinated vimentin of 50 kDa and is present in rheumatoid synovial; Sa seems to be a clue of a causal elusive

event of arthritis; interestingly the enzymes peptidyl-arginil-deiminases 2 and 4 that transform the arginine in citrulline, are both present in the synovial of patients with rheumatoid arthritis but not in normal synovial tissue (10, 11).

Molecular mimicry

Some viral proteins may cross react with human intermediate filaments (12); additionally some molecules like the lysogangliosides and the N-acetylglucosamine from the Streptococcus A group which are major epitops in rheumatic fever, are clinically linked to the Sydenham chorea and to rheumatic cardiomyopathy (13). Another example of molecular mimicry is the anti-phospholipid syndrome caused by antibodies against beta 2 glycoprotein I (b2GPI); the possible link of an anti-phospholipid antibody and infections is attributed to the hexapeptide TLRVYK shared by b2GPI with microorganisms such as Haemophilus influenzae and Neisseria gonorrhoeae (14, 15). Chemicals like the milk butirophylin (BTN) may produce cross reactivity with the extra-cellular NH3 domain of the oligodendrocyte myelin (MOG); in multiple scler-

Table 1 - Some autoantigens cleaved by proteases. Adapted from Utz et al. (113)

Disease	Autoantigen	Cleavage site	Protease
Autoimmune Hepatitis	Actin	LVID ₁₁ , ELPD ₂₄₄	C1
Coeliac Disease	Transglutaminase	Various	3
MCTD	U1-70 kD	DGPD ₃₄₁ /LGND ₄₀₉	3/GB
Overlap Syndrome	DNA-PK	DEV ₂₇₁₂	C3
		VGPD ₂₆₉₈	GB
Poly/Dermatomyositis	Alanyl tRNA synthetase Histidyl tRNA synthetase Isoleucyl tRNA synthetase Mi-2 PM-Scl (overlap syndrome)	VAPD ₆₃₂	GB
		LGPD ₄₈	GB
		VTPD ₉₈₃	GB
		VDPD ₁₃₁₂	GB
		VEQD ₂₅₂	GB
Scleroderma	CENP-B Fibrillarlin hnRNP C1 and C2 PM-Scl RNA polymerase I and II Topoisomerase I SR protein kinase	VSD ₄₅₇	GB
		VGPD ₁₈₄	GB
		Various	C 3, 6, 7
		VEQD ₂₅₂	GB
		ICPD ₄₄₉ /ITPD ₃₇₀	GB
		DDVD _{146r} /EEED ₁₇₀	C3
		PEDD ₁₂₃ /IEAD ₁₅	C 3, 6/GB
Sjogren's disease	NuMA α -Fodrin UBF/NOR-90\ Vimentin	Various/VATD ₁₇₀₅	C 3, 4, 6, 7, 8/GB
		Various	Caspases
		Various/VRPD ₂₂₀	GB
		IDVD ₂₅₉	C 1, 2, 3, 8, 12
SLE	Ki-67 Ku-70 La Lamin A, B PARP	VCTD ₁₄₈₁	GB
		ISSD ₇₉	GB
		DEHD ₃₇₁ , DEHD ₃₇₄	C 2, 3, 8, 9
		VEID _{230r} , EEID _{448r} , VEID ₂₃₀	C 6, ?, 6
		DEV ₂₁₆ /VDPD ₅₃₆	C 1, 2, 3, 6/GB

C = Caspases, GB = Granzyme B.

rosis the presence of anti-BTN antibodies in cerebrospinal fluid suggest a shared epitope of MOG/BTN₇₆₋₁₀₀ with myelin; this data suggest that a molecule present in the diet may stimulate the pre-existing autoimmune clones (16).

Autoantibodies are clinical markers

Autoimmune diseases are widely distributed; they are mediated by antibodies and reactive cells to self antigens. Clinically the diseases are classified in systemic diseases such as systemic lupus erythematosus and organ specific like the pemphigus. Autoantibodies are markers of autoimmune disease and recognize specific antigens; in some instances these autoantibodies are pathogenic because they participate directly in tissue damage; in other instances are predictors of the clinical outcome (17-19). Additionally, the autoantibodies may help to study the molecular modifications of self antigens induced by apoptosis (20). Autoimmune diseases affect more than 10 millions of Americans, among the "top ten autoimmune diseases" are: Graves disease, rheumatoid arthritis, Hashimoto thyroiditis, vitiligo, type 1 diabetes, pernicious anemia, multiple sclerosis, glomerulonephritis, systemic lupus erythematosus and Sjögren's disease, they have an autoantibody marker (21). Diverse autoantibodies may recognize native autoantigens and/or molecules modified by apoptosis (Tab. I).

Apoptosis

Is a physiologic process that guarantees the cellular exchange and produce cellular changes such as tightening, membrane blebbing, DNA fragmentation and mitochondrial release of cytochrome C. Apoptosis and necrosis are different because the latter is passive and induce cell disruption with inflammation; meanwhile the apoptosis is active and is developed without inflammation and not release of intracellular material. Along life a healthy individual produce 1×10^{20} Kg of cellular debris that is cleaned by phagocytosis. During apoptosis the intracellular self-antigens are translocated to cell surface and become available to pre-existing autoimmune repertoires (22, 23).

Extrinsic pathway

Involves the tumor necrosis factor family receptors (TNFR) leaded by Fas (CD95/Apo-1), they activate a signal transduction that recruits and activates the caspase-8, that in turn cleaves of the downstream effector's caspases. The intrinsic or mitochondrial pathway is triggered inside of the

cell by direct caspase activation or by intracellular changes that release pro-apoptotic mitochondrial factors, this activate the caspase 9 that in turn trigger the effector's caspases inside the apoptosome. The molecular link between both pathways is Bid which is a member of Bcl-2 family that is translocated to mitochondrial membrane by the cleavage induced by Caspase 8; Bid produce pro-apoptotic changes (24). The proteins involved in apoptosis are: Cell surface receptors and intracellular proteins including caspases.

Receptors of death cell

Includes eight main members:

1. Tumor necrosis factor receptor or DR1 (CD120a, p55 and p60).
2. Fas or DR2 (CD95, APO1).
3. DR3 (APO-3, LARD, TRAMP, and WSL1).
4. TNF-related apoptosis-inducing ligand receptor or TRAILR1 (DR4, APO 2).
5. TRAILR2 (DR5, KILLER, TRICK2).
6. DR6.
7. Ectodysplasin A receptor or EDAR,
8. Nerve growth factor receptor.

The extra cellular domains of death cell receptors contain a variable number of cysteine-rich domains, which are activated by their respective ligands: for instance TNF α activate TNF-R1, FasL and TL1A activate Fas and DR3 respectively, TRAIL activates DR4 and DR5, the ligand of DR6 remain to be identified. The intracellular "death domain" (DD) of each receptor is required for the signaling transduction, because it recruits different molecules that activate the caspases cascade. The death ligands interact simultaneously with the decoy receptors (DcR) and with osteoprotegrin (OPG), but do not transduces signals (25-33).

Caspases

This family of intracellular enzymes contain cysteins in a highly conserved active site (QACRG), this pentapeptide cleave at the aspartic residues of the target protein, working like "molecular scissors". The caspases are produced as proenzymes; they contain an amino-terminal caspase recruiting domain (CARD) and two subunits: one large (p20) and another small (p10), the caspases associates in a heterodimeric active form, and then the CARD prodomain is removed (34). The active caspase 3 and caspase 6 cleaves the death substrate poly(ADP-ribose) polymerase (PARP) which is a DNA damage signal protein, that interacts in a non-covalent fashion with different proteins altering

their functions (35, 36). In *Drosophila* there are 7 different caspases, meanwhile in mammals there are 14. The caspases with large prodomains are 1, 2, 4, 5, 8, 9, 10, 11, 12 and 13.

Death receptor signaling complex

Functionally the receptors are classified in two groups: the first group comprises a death-inducing signal complexes (DISCs) formed by Fas, TRAILR1 or TRAILR2 which recruit the same DISC machinery (FAAD), pro-caspase 8/10 and FLIP_{L/S}; the death effector's domain (DED) of FAAD work together with the DED of procaspase 8 and 10 and FLIP, this complex activates caspase 8 that in turn cleaves procaspases 3, 7 and 6; by this way the Lamin A, Actin, Gas2, Fodrin, Gelsolin, PKC, PARP, ICAD and Rb are attacked, this cleavage results in cell shrinkage, membrane blebbing and DNA fragmentation (37). There are two types of Fas signaling, the type I is of high performance in the DISC formation and produce large amounts of active caspase 8, meanwhile the type II is a low performance in the Fas-DISC complex formation and low caspase 8 level, this is compensated by a release of cytochrome c through a truncated Bid, cleaved by caspase 8.

The liberation of cytochrome c results in the apoptosome formation that is followed by the activation of procaspase 9 which cleaves the effector's caspases (33, 38-40). The second group of receptors engages TNFR1, DR3, DR6 and EDAR which transduce apoptotic signals by two different signaling complexes: The complex I formed at the membrane and includes: TNFR1, TNF, RIP (receptor-interacting protein), TRADD (TNFR-associated death domain protein), TRAF-1/2 (TNFR associated factor); the complex I initiate the NF- κ B activation by IKK recruitment and JNK activation and depends of a TRAF-2 mechanism without FAAD, and the activation of NF- κ B transcription leads the expression of survival genes (33, 41). The complex II implies the traddosome formation, therefore the amount of FLIP determine whether caspase-8 is activated (42, 43).

Mitochondrial pathway

Cell death signals of the intrinsic pathway are leaded by proteins of the Bcl-2 family, such as the cytochrome C, Smac/Diablo and others that activate the caspases cascade. The procaspase 9 is recruited and activated by the heptameric "apoptosome" which is formed by the released cytochrome C that bind monomers of Apaf-1 and catalyzes the acti-

vation of caspase 9, this activates the effector's caspases-3, 6 and 7 leading apoptosis (44-46).

Clearance of apoptotic material

After apoptosis the cellular remains are quickly cleaned by phagocytes, which recognize tags on the surface of apoptotic cells; the phosphatidylserine (PS) is one of them and it is negatively charged in the inner membrane bilayer, by apoptosis PS is translocated to cell surface and interacts with phagocytes and macrophages. Another tag is the lysophosphatidylcholine that operates as a soluble phagocyte attractant (47). PS is identified by phagocytes through the phosphatidylserine receptor (PSR) that trigger a signal transduction. Other receptors involved in recognition are: α V β 3 integrin, CD36, CD68, CD14, ABC1 (ATP binding cassette transporter), β_2 -GP1R (β_2 -glycoprotein 1 receptor), β_2 -integrin receptor and Calreticulin. There are other ligands and receptors that participate in the "phagocytic synapse" these include C1q, β_2 -GP1, MFG8, thrombospondin 1 and oxidated LDL. The pentraxines such as CRP and seric amyloid (SAA), as well as the complement fractions C4 and C2 are involved in the clearance (48).

Autoimmunity and apoptosis

Apoptosis is essential during the lymphoid ontogeny; the immature T cells lacking of functional T-cell receptors (TCR) "die by neglect" because they express low levels of Bcl-2, this activate the mitochondrial pathway (49). In addition, the TCR with strong self reactivity are eliminated centrally by the Fas pathway (50). Autoimmune B cells under development may also die by apoptosis which is induced by BCR cross linking and the lacking of IL-4, CD40L and BAFF co-stimulation. In the periphery the B cells requires at least two signals to live:

1. The intrinsic expression of BCR on cell surface
2. The signaling induced by the cytokine BAFF; the BAFF transgenic mice increase importantly the number of mature B and effector's T cells, and develop autoimmune-like manifestations like high levels of rheumatoid factor, circulating immune complexes, anti-DNA autoantibodies, and immunoglobulin deposition in the kidneys (51, 52).

Defect of the Fas pathway

Mutations of Fas receptor and/or FasL, and the kinases involved in signal transduction of Fas have been implicated in autoimmunity. Canale and

Smith described a clinical picture in children with non malignant lymphadenopathies associated with autoimmunity; this clinical entity was called ALPS (53). After clinical description, the molecular basis for this disorder was demonstrated in MLR *lpr* mice; these animals develop glomerulonephritis, lymphadenopathies, hypergammaglobulinemia and antinuclear antibodies (54). Other mutants such as the *lpr^{cg}* and *gld* mice, develop deficiency in Fas expression by a missense mutation of the extra cellular domain of FasL, this mutation abolish the ligand function (55). The ALPS patients exhibit clinical and functional variants in the expression of Fas (56-59), this defect up-regulates CD28 that produce activation and proliferation of autoreactive T cell clones, that in turn activate the Fas-deficient B cells which produce autoantibodies (60); nevertheless a deficiency in autoimmune clonal elimination by the Fas pathway seems to affect more the peripheral tolerance rather than the central control, because the negative selection into the thymus is not impaired in the *lpr* mice (61).

Defect of the mitochondrial pathway

The engagement of B cell receptor (BCR) in developing o mature B cells, prevents the B cell autoimmunity in absence of T help; however the absence of the pro-apoptotic Bcl-2 family member Bim, make refractory the B cells to commit apoptosis by BCR ligation, in consequence this deficiency allows the survival of autoimmune clones that may result in a SLE-like disease (62, 63).

Defect in clearance

The presence of molecules from innate immunity on the surface of apoptotic cells, enhance the cleaning of apoptotic material by macrophages. Patients with autoimmune diseases associated to complement deficiencies, are impaired to clean properly the apoptotic material (64, 65). For instance the C1q deficiency result in SLE; the C1q-deficient (*C1qa^{-/-}*) mice develop spontaneous antinuclear antibodies with glomerulonephritis, therefore the presence of huge amounts of glomerular apoptotic bodies precede any clinical manifestation, it seems appear that the abnormal presence of autoantigens in glomerulus's is determinant for the formation of immune complexes *in situ* (66-68); the coating of apoptotic cells by the C3bi, CR3 and CR4 fractions is necessary for the engulfment of apoptotic material (69). Not only deficiencies in the complement fractions may induce autoimmunity, also some mutations in the complement re-

ceptors are associated to SLE, for example the CR1, CR2 that are crucial for the cleaning pathway as demonstrated NZM2410 mice, furthermore the *Cr2* gene deficiency confer susceptibility to SLE (70). Other molecules like the mannose-binding lectin (MBL) that behave structural and functionally as C1q and bind apoptotic cells in a late stage of apoptosis are important for cleaning the apoptotic material, but not determinant for autoimmune development, MBL null mice that develop defects in clearance do not develop spontaneous autoimmunity, lymphoproliferation, or germinal centers expansion as expected, rather they develop increased numbers of B1 cells (71, 72). A variant polymorphism of MBL gene produce low amounts of MBL and is associated to dermatomyositis (73). In summary, the insufficient clearance of apoptotic material may result in a high concentration of native or modified antigens which are potential targets of autoimmune clones.

Apoptosis induces nucleic acids and ribonucleoproteins fragmentation

The chromatin fragmentation is the hallmark of apoptosis; this is leaded by caspase-3, that activates the DNA fragmentation factor (DFF) or caspase-activated DNase (CAD) that in turn cut the DNA in ~200 bp fragments. Another endonuclease G (Endo G) contribute to DNA degradation; both endonucleases attack the chromatin and yield 3'-hydroxyl groups of 50-300 kb cleavage products, and 5'-phosphate residues at the level of internucleosomal DNA fragmentation (74). After fragmentation the apoptotic DNA bind the phosphatidylethanolamine and phosphatidylserine of apoptotic membranes and become accessible to APC throughout blebs, it seems appear that the cleaved DNA induce maturation of bone marrow-derived dendritic cells. Additionally, the DNA methylation as well as the IFN-alpha participation are critical for anti-DNA production (75-79).

Apoptosis affects the nucleolus and nucleoplasmic RNP containing structures

They suffer significant changes during apoptosis (80); this changes involve the rRNA degradation by the Fas pathway, which occurs at the 3'-end region of 28S rRNA, therefore the caspase-3 expose part of the large subunit; additionally, different ribonucleases caspase dependent (CARs) are activated and produce extrusion of the nuclear RNP structures to the cell surface; also during apoptosis mRNAs are cleaved previously to eIF4GI and

other initiation factors, this cleavage may result in anti-nucleolar antibody production in diseases like scleroderma (81-85). Patients suffering of the autoimmune mixed connective tissue disease produce huge amounts of anti-U1-70RNP autoantibody, and this ribonucleoprotein is one of the most affected by apoptosis, therefore the caspase 3 cleaves U1 70 RNP at position ³³⁸DGPD₃₄₁, and the fragmentation increases its antigenicity (86-88); interestingly the anti-RNP autoantibodies recognize preferentially the apoptotic epitope of U1-70K (89).

Additionally it has been demonstrated that the truncated fragments of U1A and U1C are more reactive to anti-RNP antibodies (90). Other small ribonucleoproteins like the Sm-F peptide is modified by caspase 8 and by proteases of the mitochondrial pathway (91). The cleavage of U1 snRNA occurs at the 5'-side of either Ψ 6 or Ψ 7 in the single-stranded 5'-end of the snRNA, the flanking pseudouridines are involved in the cleavage sites. Other small U2, U3, U4, U5 and U6 snRNA molecules are not modified by apoptosis (92). The heterogenous nuclear ribonucleoproteins (hnRNP) are cleaved by caspases, resulting fragments of 32, 29, and 16 kDa (93); other RNA binding proteins modified by apoptosis include hnRNP A1, hnRNP C1/C2, FUSE binding protein, nucleolin, Rho GDI 2, and the transcription factor BTF3 (94). The small hYRNAs complexed with Ro and La are degraded by caspase 3; such degradation is inhibited by Zinc and by caspase inhibitors and by Bcl-2 (95).

In apoptosis, Ro remains bound to a highly conserved region of the hYRNA, such binding protect of degradation to one 22 to 36 nucleotides domain; La ribonucleoprotein which is also associated with the hYRNAs, behave in similar manner and protects 27 to 36 nucleotides of the hYRNA (92, 96), apparently Ro60 protein is not cleaved by caspases or granzyme, however by apoptosis Ro suffer self-aggregation (97, 98). The ribonucleoprotein La is cleaved by caspase 3 at Asp-374 in the COOH terminus (99). At least 420 autoantigens are cleaved by apoptosis among them are: DNA-PK, NuMA, topoisomerase I, Fordin hnRNP C1 and C2, La, Lamin A, NuMA, PARP, Topoisomerase I and Vimentin among others (97, 99, 100). Table I. Another way of autoantigen cleavage is induced by the cytotoxic lymphocytes, therefore the activated CD8 cells (CTLs) and NK cells release toxic granules containing granzyme B; during viral infection the cytotoxic cells may release

granzyme B, this also may occur in cancer; the granzyme B cleaves and activates several pro-caspases and other proteins in different sites than caspases (99-102). Among autoantigens cleaved by granzyme B are: DNA-PKcs, NuMA, Histidyl tRNA synthase, Alanyl tRNA synthase, CENP-B, Fibrillarlin, Ku-70, La, Mi-2, PARP, PM-Scl, PMS1 -2, RNA polymerase I-II, Topoisomerase I and U1-70 kD (98,103).

Phosphorylation induces autoantigen cleavage

The splicing factors (SR) are phosphorylated during apoptosis, for instance the SR, ASF/SF2 and SC35 factors which are associated with the spliceosome and the splicing factor kinases (SRPKs), are activated by sub-lethal stress, this trigger an alternative splicing of anti-apoptotic mRNAs bcl-xl and Ich1 isoforms, nevertheless by lethal stress the SRPK1 activity is shut down by caspase mediated proteolysis, therefore the regulation, localization and possible modifications of the SR autoantigens depends of the stress level (104, 105). The cellular stress induces association of diverse phosphoproteins with the small nucleolar RNPs, such association may trigger the autoantibody production in diseases like scleroderma, were autoantigens like the snoRNPs form part of a phosphoprotein complex composed by fibrillarlin and the serine/arginine (SR) splicing factors such as SRp40, the phosphorylated complex may trigger an antibody response against fibrillarlin (106).

The IL-1B converting enzyme (ICE) family proteases cleaves the poly (A) ribose polymerase and the U1 70-kD snRNP, also cut the DNA-dependent protein kinase (DNA-PK) and the nuclear mitotic apparatus protein and the Lamin B; ICE protease operates in the effector's phase of apoptosis cleaving phosphoproteins; therefore the cleavage and phosphorylation are not necessarily mutually exclusive events, however it is possible that the phosphorylation of serine in autoantigens may promote the cleavage mediated by ICE-like protease in domains of DNA-PK, this is the case of U1-70 kD, nuclear Lamin B and UBF/Nor-1 (107).

Other targets of apoptosis are the Golgi apparatus proteins: Giantin/macrogolgin/GCP372, golgin-245/p230, golgin-160/GCP170, golgin-95/GM130, golgin-97, and golgin-67, they have coiled-coil domains (108-110), and the Golgin-160 contains at the N-terminal head domain several putative binding domains, and regulatory motifs and phosphorylation sites. It has been demonstrated that a caspase-dependent cleavage of the golgin-160 head

Table II - Examples of chemically induced autoimmunity.

Chemical	Disease	Autoantibody	Mechanism involved	References
Procainamide	Lupus	Anti-histone	Apoptosis, DNA metylation	117-119
Isoniazid	Lupus	ANA, anti-histone	Slow acetylator genotypes	120-122
Methylodopa	Lupus	H2A-H2B-nDNA, anti-erythrocyte	Lupus	123
Hydralazine	Lupus	ANA	ERK pathway inhibition	119, 124, 125
Chloropromazine	Lupus	ANA	Apoptosis	126, 127
Quinidine	Lupus	ANA, anti-chromatin	Apoptosis	118, 128
Sulphasalazine	Lupus	ANA	Slow acetylator genotypes	129, 130
Carbamazepin	Lupus	ANA, Anti-histone	Increase of B cell activity	131, 132
Phenytoin	Hepatitis	Anti-CYP3A	Drug-metabolizing enzymes	133
	IgA bullous dermatosis Lupus	Anti-histone	Moderate apoptosis inductor Low endogenous levels of dehydroepiandrosterone	134, 135 136
Propylthiouracil Methimazole	Lupus, vasculitis,	ANA, anti-dsDNA, ANCA	Apoptosis	137, 138
D-Penicillamine	Autoimmune syndrome	ANA Anti-epithelial antibodies	Cell stress	139
Chlorothiazide and hydrochlorothiazide	Cutaneous lupus erythematosus	Anti-Ro		140
Beta blockers	Lupus	ANA, anti-histone, anti-ssDNA antibodies	Polyclonal stimulation of lymphocytes	141,142
Valproic acid	Lupus	anti-dsDNA ANA, antiphospholipid antibody	Metabolite valpromide	143, 144
Terbinafine	SCLE	ANA, anti-Ro, anti-histone (H1 and H3)	HLA-B8,DR3 haplotype;	145, 146
Mercury	Scleroderma	Anti-Fibrillarin-U3	Apoptosis	147, 148

domain occurs rapidly after apoptosis induction, and the caspase cleavage at Asp139 site depend of a previous phosphorylation carried out by MLK3 (111).

Dephosphorylation occurs less frequently during apoptosis, for example La autoantigen is dephosphorylated at serine 366, and it seems appear that the kinase inactivation and the up-regulation of phosphatase A2 may produce dephosphorylation of La (112, 113). Another group of autoantigens dephosphorylated by apoptosis is the ribosomal proteins; anti-P ribosomal autoantibodies recognize all P proteins dephosphorylated by apoptosis, such process modify the conformational determinants of P proteins at the COOH end, this conformational modification foster the autoantibody production (114).

Autoantibodies and pharmaceutical agents

Autoimmunity can be triggered by the use of different pharmaceutical agents, also the chronic intoxication with metals have been ascribed to chemical induced autoimmunity, the molecular mechanisms that participate in this process are: 1. The inhibition of the DNA methylation may activate the

T cells. 2. Production of reactive metabolites that interfere with the tolerance. 3. Activation of antigen presenting cells (APCs) by drugs or metals 4. Drug induced apoptosis, as is the case of the chemotherapy increases the cellular debris and may trigger the autoantibody production (115). The clinical association between drugs and autoimmunity was reported since 1945, a patient who developed lupus after treatment with sulfadiazine; then in 1953 some cases of lupus related to the use of hydralazine were reported (116), subsequently other publications pointed out the role of hydralazine in triggering the antinuclear antibody production (117). More than 80 drugs may induce autoimmunity; most of them induce lupus and other diseases. Drugs include anti-hypertensive, anticonvulsivants, diuretics, anti-thyroidal drugs, antiarrhythmics, anti-tumoral therapy and by chronic intoxication with heavy metals (117-152) (Tab. II).

In summary, the tolerance would be shut down by diverse factors which would drive the autoantibody production in individuals genetically predisposed.

Acknowledgements

Supported by PROMEP-UAZ-CA-5.

SUMMARY

Apoptosis is the physiologic process that guarantees the cellular exchange; after apoptosis the cellular remains are cleared by phagocytosis. In autoimmunity, some mechanisms in apoptosis fail and may result in disease. For instance, a failure in the Fas pathway during lymphoid ontogeny may allow the survival of autoimmune clones; equally the lack of clearance of apoptotic corps containing self-antigens may activate pre-existent auto-reactive clones and may result in autoantibody production. The role of apoptosis in autoimmunity is reviewed.

Key words - Apoptosis, autoimmunity, autoantibodies, caspases, Fas/FasL.

Parole chiave - Apoptosi, autoimmunità, autoanticorpi, caspasi, Fas/FasL.

REFERENCES

- Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. *J Exp Med* 1994; 179: 317-30.
- Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. Predominant autoantibody production by early human B cell precursors. *Science* 2003; 301: 1374-7.
- Kompfner E, Oliveira P, Montalbano A, Feeney AJ. Unusual germline DSP2 gene accounts for all apparent V-D-D-J rearrangements in newborn, but not adult, MRL mice. *J Immunol* 2001; 167: 6933-8.
- Kleinstein S, Louzoun Y, Shlomchik MJ. Estimating hypermutation rates from clonal tree data. *J Immunol* 2003; 171: 639-49.
- Diamond B, Scharff MD. Somatic mutation of the T15 heavy chain gives rise to an antibody with autoantibody specificity. *Proc Natl Acad Sci USA* 1984; 81: 5841-44.
- Fraser NLW, Rowley G, Field M, Stott DI. The VH gene repertoire of splenic B cells and somatic hypermutation in systemic lupus erythematosus. *Arthritis Res Ther* 2003; 5: R114-21.
- Christen U, von Herrath MG. Induction, acceleration or prevention of autoimmunity by molecular mimicry. *Mol Immunol* 2004; 40: 1113-20.
- Arbuckle MR, Reichlin M, Harley JB, James JA. Shared early autoantibody recognition events in the development of anti-Sm B/B' in human lupus. *Scand J Immunol* 1999; 50: 447-55.
- Li N, Aoki V, Hans-Filho G, Rivitti EA, Diaz LA. The role of intramolecular epitope spreading in the pathogenesis of endemic pemphigus foliaceus (fogo selvagem). *J Exp Med* 2003; 197: 1501-10.
- Ménard HA, Lapointe E, Rochdi MD, Zhou Z. Insights into rheumatoid arthritis derived from the Sa immune system. *Arthritis Res* 2000; 2: 429-32.
- Vossenaar ER, Despres N, Lapointe E, Van Der Heijden A, Lora M, Senshu T, et al. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. *Arthritis Res Ther* 2004; 6: R142-50.
- Oldstone MBA. Molecular mimicry and immune-mediated diseases. *FASEB J* 1998; 12: 1255-65.
- Kirvan CA, Swedo SE, Heuser JS, Cunningham MW. Mimicry and autoantibody-mediated neuronal cell signaling in Sydenham chorea. *Nat Med* 2003; 9: 914-20.
- Blank M, Krause I, Fridkin M, Keller N, Kopolovic J, Goldberg I, et al. Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. *J Clin Invest* 2002; 109: 797-804.
- Asherson RA, Cervera R. Antiphospholipid antibodies and infections. *Ann Rheum Dis* 2003; 62: 388-93.
- Guggenmos J, Schubart AS, Ogg S, Andersson M, Olsson T, Mather IH, et al. Antibody cross-reactivity between myelin oligodendrocyte glycoprotein and the milk protein butyrophilin in multiple sclerosis. *J Immunol* 2004; 172: 661-8.
- Rose NR. Autoimmune disease 2002: an overview. *J Invest Dermatol Symp Proc* 2004; 9: 1-4.
- Lernmark Å. Autoimmune diseases: are markers ready for prediction? *J Clin Invest* 2001; 108: 1091-6.
- Leslie D, Lipsky P, Notkins AL. Autoantibodies as predictors of disease. *J Clin Invest* 2001; 108: 1417-22.
- Fritzler MJ. Autoantibodies: diagnostic fingerprints and etiologic perplexities. *Clin Invest Med* 1997; 20: 50-66.
- Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. *Clin Immunol Immunopathol* 1997; 84: 223-43.
- Lorenz HM, Herrmann M, Winkler T, Gaipl U, Kalden JR. Role of apoptosis in autoimmunity. *Apoptosis* 2000; 5: 443-9.
- Qian Y, Wang H, Clarke SH. Impaired clearance of apoptotic cells induces the activation of autoreactive anti-Sm marginal zone and B-1 B cells. *J Immunol* 2004; 172: 625-35.
- Barnhart BC, Alappat EC, Peter ME. The CD95 type I/type II model. *Semin Immunol* 2003; 15: 185-93.
- Schall TJ, Lewis M, Koller KJ, Lee A, Rice GC, Wong GH, et al. Molecular cloning and expression of a receptor for human tumor necrosis factor. *Cell* 1990; 61: 361-70.
- Smith CA, Davis T, Anderson D, Solam L, Beckmann MP, Jerzy R, et al. receptor for tumor necrosis

- factor defines an unusual family of cellular and viral proteins. *Science* 1990; 248: 1019-23.
27. Oehm, A, Behrmann, I, Falk W, Pawlita, M, Maier, G, Klas, C, et al. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. *J Biol Chem* 1992; 267: 10709-15.
 28. Bhardwaj A, Aggarwal BB. Receptor-mediated choreography of life and death. *J Clin Immunol* 2003; 23: 317-32.
 29. Shakibaei M, Schulze-Tanzil G, Takada Y, Aggarwal BB. Redox regulation of apoptosis by members of the TNF superfamily. *Antioxid Redox Signal* 2005; 7: 482-96.
 30. Sheikh MS, Huang Y. Death receptors as targets of cancer therapeutics. *Curr Cancer Drug Targets* 2004; 4: 97-104.
 31. Itoh N, Nagata S. A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen. *J Biol Chem* 1993; 268: 10932-7.
 32. Chew LJ, Pan H, Yu J, Tian S, Huang WQ, Zhang JY, Pang S, et al. A novel secreted splice variant of vascular endothelial cell growth inhibitor. *FASEB J* 2002; 16: 742-4.
 33. Lavrik I, Golks A, Krammer PH. Death receptor signaling. *J Cell Sci* 2005; 118: 265-7.
 34. Ellis HM, Horvitz HR. Genetic control of programmed cell death in the nematode *C. elegans*. *Cell* 1986; 44: 817-29.
 35. Camerini D, Walz G, Loenen WA, Borst J, Seed B. The T cell activation antigen CD27 is a member of the nerve growth factor/tumor necrosis factor receptor gene family. *J Immunol* 1991; 147: 3165-9.
 36. Pleschke JM, Kleczkowska HE, Strohm M, Althaus FR. Poly(ADP-ribose) binds to specific domains in DNA damage checkpoint proteins. *J Biol Chem* 2000; 275: 40974-80.
 37. Peter ME, Krammer PH. The CD95(APO-1/Fas) DISC and beyond. *Cell Death Differ* 2003; 10: 26-35.
 38. Korsmeyer SJ, Wei MC, Saito M, Weiler S, Oh KJ, Schlesinger PH. Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. *Cell Death Differ* 2000; 7: 1166-73.
 39. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, et al. Two CD95 (APO-1/Fas) signaling pathways. *EMBO J* 1998; 17: 1675-87.
 40. Willis S, Day CL, Hinds MG, Huang DC. The Bcl-2-regulated apoptotic pathway. *J Cell Sci* 2003; 116: 4053-6.
 41. Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. *Cell* 2003; 114: 181-90.
 42. French LE, Tschopp J. Protein-based therapeutic approaches targeting death receptors. *Cell Death Differ* 2003; 10: 117-23.
 43. Golks A, Brenner D, Fritsch C, Krammer PH, Lavrik IN. c-FLIPR, a new regulator of death receptor-induced apoptosis. *J Biol Chem* 2005; 280: 14507-13.
 44. Degli Esposti M. Mitochondria in apoptosis: past, present and future. *Biochem Soc Trans* 2004; 32: 493-5.
 45. Nicholson DW, Thornberry NA. Apoptosis. Life and death decisions. *Science* 2003; 299: 214-5.
 46. Jiang X, Kim HE, Shu H, Zhao Y, Zhang H, Kofron J, et al. Distinctive roles of PHAP proteins and prothymosin-alpha in a death regulatory pathway. *Science* 2003; 299: 223-6.
 47. Lauber K, Blumenthal SG, Waibel M, Wesselborg S. Clearance of apoptotic cells: getting rid of the corpses. *Mol Cell* 2004; 14: 277-87.
 48. Savill J, Gregory C, Haslett C. Cell biology. Eat me or die. *Science* 2003; 302: 1516-7.
 49. Sohon SJ, Rajpal A, Winoto A. Apoptosis during lymphoid development. *Curr Opin Immunol* 2003; 15: 209-16.
 50. Sprent J, Kishimoto H. The thymus and negative selection. *Immunol Rev* 2002; 185: 126-35.
 51. Schiemann B, Gommerman JL, Vora K, Cachero TG, Shulga-Morskaya S, Dobles M, et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. *Science* 2001; 293: 2111-4.
 52. Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. *J Exp Med* 1999; 190: 1697-710.
 53. Canale VC, Smith CH. Chronic lymphadenopathy simulating malignant lymphoma. *J Pediatr* 1967; 70: 891-9.
 54. Nagata S, Golstein P. The Fas death factor. *Science* 1995; 267: 1449-55.
 55. Nagata S, Suda T. Fas and Fas ligand: *lpr* and *gld* mutations. *Immunol Today* 1995; 16: 39-43.
 56. Rieux-Laucat F, Le Deist F, Hivroz C, Roberts I, Debatin K, Fischer A, et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. *Science* 1995; 268: 1347-9.
 57. Rieux-Laucat F, Le Deist F, Fischer A. Autoimmune lymphoproliferative syndromes: genetic defects of apoptosis pathways. *Cell Death Differ* 2003; 10: 124-33.
 58. Di Cristofano A, Kostic P, Peng YF, Cordon-Cardo C, Elkon KB, Pandolfi PP. Impaired Fas response and autoimmunity in *Pten*^{+/-} mice. *Science* 1999; 285: 2122-5.
 59. Vaishnav AK, Orlinick JR, Chu JL, Krammer PH, Chao MV, Elkon KB. The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations. *J Clin Invest* 1999; 103: 355-63.
 60. Rathmell JC, Cooke MP, Ho WY, Grein J, Townsend SE, Davis MM, et al. CD95 (Fas)-dependent elimination of self-reactive B cells upon interaction with CD4⁺ T cells. *Nature* 1995; 376: 181-4.
 61. Singer GG, Abbas A K. The fas antigen is involved in peripheral but not thymic deletion of T lymphocytes.

- tes in T cell receptor transgenic mice. *Immunity* 1994; 1: 365-71.
62. Bouillet P, Metcalf D, Huang DCS, Tarlinton DM, Kay TWH, Köntgen F, et al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. *Science* 1999; 286: 1735-8.
 63. Enders A, Bouillet P, Puthalakath H, Xu Y, Tarlinton DM, Strasser A. Loss of the pro-apoptotic BH3-only Bcl-2 family member Bim inhibits BCR stimulation-induced apoptosis and deletion of autoreactive B cells. *J Exp Med* 2003; 198: 1119-26.
 64. Shoshan Y, Shapira I, Toubi E, Frolkis I, Yaron M, Mevorach D. Accelerated Fas-mediated apoptosis of monocytes and maturing macrophages from patients with systemic lupus erythematosus: relevance to in vitro impairment of interaction with iC3b-opsonized apoptotic cells. *J Immunol* 2001; 167: 5963-9.
 65. Taylor PR, Carugati A, Fadok VA, Cook HT, Andrews M, Carroll MC, et al. A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. *J Exp Med* 2000; 192: 359-66.
 66. Pickering MC, Botto M, Taylor PR, Lachmann PJ, Walport MJ. Systemic lupus erythematosus, complement deficiency, and apoptosis. *Adv Immunol* 2000; 76: 227-324.
 67. Botto M, Dell'Agnola C, Bygrave AE, Thompson EM, Cook HT, Petry F, et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. *Nat Genet* 1998; 19: 56-9.
 68. Korb LC, Ahearn JM. C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes: complement deficiency and systemic lupus erythematosus revisited. *J Immunol* 1997; 158: 4525-8.
 69. Mevorach D, Mascarenhas JO, Gershov D, Elkon KB. Complement-dependent clearance of apoptotic cells by human macrophages. *J Exp Med* 1998; 188: 2313-20.
 70. Boackle SA, Holers VM. Role of complement in the development of autoimmunity. *Curr Dir Autoimmun* 2003; 6: 154-68.
 71. Nauta AJ, Raaschou-Jensen N, Roos A, Daha MR, Madsen HO, Borrias-Essers MC, et al. Mannose-binding lectin engagement with late apoptotic and necrotic cells. *Eur J Immunol* 2003; 33: 2853-63.
 72. Stuart L.M, Takahashi K, Shi L, Savill J, Ezekowitz RAB. Mannose-binding lectin-deficient mice display defective apoptotic cell clearance but no autoimmune phenotype. *J Immunol* 2005; 174: 3220-6.
 73. Werth VP, Berlin J.A, Callen JP, Mick R, Sullivan KE. Mannose binding lectin (MBL) polymorphisms associated with low MBL production in patients with dermatomyositis. *J Invest Dermatol* 2002; 119: 1394-9.
 74. Widlak P, Garrard WT. Discovery, regulation, and action of the major apoptotic nucleases DFF40/CAD and endonuclease G. *J Cell Biochem* 2005; 94: 1078-87.
 75. Bave U, Alm GV, Ronnblom L. The combination of apoptotic U937 cells and lupus IgG is a potent IFN-alpha inducer. *J Immunol* 2000; 165: 3519-26.
 76. Mathian A, Weinberg A, Gallegos M, Banchereau J, Koutouzov S. IFN-alpha induces early lethal lupus in preautoimmune (New Zealand Black x New Zealand White) F1 but not in BALB/c mice. *J Immunol* 2005; 174: 2499-506.
 77. Cabrespines A, Laderach D, Lebosse C, Bach J, Koutouzov S. Isolation and characterization of apoptotic nucleosomes, free and complexed with lupus autoantibody generated during hybridoma B-cell apoptosis. *J Autoimmun* 1998; 11: 19-27.
 78. Huck S, Deveaud E, Namane A, Zouali M. Abnormal DNA methylation and deoxycytosine-deoxyguanine content in nucleosomes from lymphocytes undergoing apoptosis. *FASEB J* 1999; 13: 1415-22.
 79. Decker P, Singh-Jasuja H, Haager S, Kötter I, Ramnense HG. Nucleosome, the main autoantigen in systemic lupus erythematosus, induces direct dendritic cell activation via a MyD88-independent pathway: consequences on inflammation. *J Immunol* 2005; 174: 3326-34.
 80. Hernandez-Verdun D, Roussel P. Regulators of nucleolar functions. *Prog Cell Cycle Res* 2003; 5: 301-8.
 81. Leung AK, Andersen JS, Mann M, Lamond AI. Bioinformatic analysis of the nucleolus. *Biochem J* 2003; 376: 553-69.
 82. Biggiogera M, Bottone MG, Scovassi AI, Soldani C, Vecchio L, Pellicciari C. Rearrangement of nuclear ribonucleoprotein (RNP)-containing structures during apoptosis and transcriptional arrest. *Biol Cell* 2004; 96: 603-15.
 83. Wilson KS, Noller HF. Molecular movement inside the translational engine. *Cell* 1998; 92: 337-49.
 84. Nadano D, Sato TA. Caspase-3-dependent and -independent degradation of 28 S ribosomal RNA may be involved in the inhibition of protein synthesis during apoptosis initiated by death receptor engagement. *J Biol Chem* 2000; 275: 13967-73.
 85. Degen WGJ, Pruijn GJM, Raats JMH, van Venrooij WJ. Caspase-dependent cleavage of nucleic acids. *Cell Death Differ* 2000; 7: 616-27.
 86. Lührmann RM, Kastner B, Bach M. Structure of spliceosomal snRNPs and their role in pre-mRNA splicing. *Biochim Biophys Acta* 1990; 1087: 265-92.
 87. Casciola-Rosen LA, Miller DK, Anhalt GJ, Rosen A. Specific cleavage of the 70-kDa protein component of the U1 small nuclear ribonucleoprotein is a characteristic biochemical feature of apoptotic cell death. *J Biol Chem* 1994; 269: 30757-60.
 88. Malmegrim KCR, Pruijn GJM, van Venrooij WJ. The fate of the U1 snRNP autoantigen during apoptosis: implications for systemic autoimmunity. *Isr Med Assoc J (IMAJ)* 2002; 4: 706-12.
 89. Hof D, Cheung K, de Rooij DJ, van den Hoogen FH, Pruijn, GJ, van Venrooij WJ, et al. Autoantibodies specific for apoptotic U1-70K are superior serologi-

- cal markers for mixed connective tissue disease. *Arthritis Res Ther* 2005; 7: R302-9.
90. Ramirez-Sandoval R, Sanchez-Rodriguez SH, Herrera-van Oostdam D, Avalos-Diaz E, Herrera-Esparza R. Antinuclear antibodies recognize cellular autoantigens driven by apoptosis. *Joint Bone Spine* 2003; 70: 187-94.
 91. Wu X, Molinaro C, Johnson N, Casiano CA. Secondary necrosis is a source of proteolytically modified forms of specific intracellular autoantigens: implications for systemic autoimmunity *Arthritis Rheum* 2001; 44: 2642-52.
 92. Degen WG, Aarssen Y, Pruijn GJ, Utz PJ, van Venrooij WJ. The fate of U1 snRNP during anti-Fas induced apoptosis: specific cleavage of the U1 snRNA molecule. *Cell Death Differ* 2000; 7: 70-9.
 93. Allemand E, Guil S, Myers M, Moscat J, Caceres JF, Krainer AR. Regulation of heterogenous nuclear ribonucleoprotein A1 transport by phosphorylation in cells stressed by osmotic shock. *Proc Natl Acad Sci USA* 2005; 102: 3605-10.
 94. Brockstedt E, Rickers A, Kostka S, Laubersheimer A, Dorken B, Wittmann-Liebold B, et al. Identification of apoptosis-associated proteins in a human Burkitt lymphoma cell line. Cleavage of heterogeneous nuclear ribonucleoprotein A1 by caspase 3. *J Biol Chem* 1998; 273: 28057-64.
 95. Thiede B, Dimmler C, Siejak F, Rudel T. Predominant identification of RNA-binding proteins in Fas-induced apoptosis by proteome analysis. *J Biol Chem* 2001; 276: 26044-50.
 96. Rutjes SA, van der Heijden A, Utz PJ, van Venrooij WJ, Pruijn GJ. Rapid nucleolytic degradation of the small cytoplasmic Y RNAs during apoptosis. *J Biol Chem* 1999; 274: 24799-807.
 97. Casiano CA, Martin SJ, Green DR, Tan EM. Selective cleavage of nuclear autoantigens during CD95 (Fas/APO-1)-mediated T cell apoptosis. *J Exp Med* 1996; 184: 765-70.
 98. Casciola-Rosen LA, Andrade F, Ulanet D, Wong WB, Rosen A. Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity. *J Exp Med* 1999; 190: 815-26.
 99. Ayukawa K, Taniguchi S, Masumoto J, Hashimoto S, Sarvotham H, Hara A, et al. La autoantigen is cleaved in the COOH terminus and loses the nuclear localization signal during apoptosis. *J Bio Chem* 2000; 275: 34465-70.
 100. Rosen A, Casciola-Rosen LA. Autoantigens as substrates for apoptotic proteases: implications for the pathogenesis of systemic autoimmune disease. *Cell Death Differ* 1999; 6: 6-12.
 101. Casciola-Rosen LA, Anhalt GJ, Rosen A. DNA-dependent protein kinase is one of a subset of autoantigens specifically cleaved early during apoptosis. *J Exp Med* 1995; 182: 1625-34.
 102. Talanian RV, Yang XH, Turbov J, Seth P, Ghayur T, Casiano CA, et al. Granule-mediated killing: pathways for granzyme B-initiated apoptosis. *J Exp Med* 1997; 186: 1323-31.
 103. Bokoch GM. Caspase-mediated activation of PAK2 during apoptosis: proteolytic kinase activation as a general mechanism of apoptotic signal transduction? *Cell Death Differ* 1998; 5: 637-45.
 104. Kamachi M, Le TM, Kim S.J, Geiger ME, Anderson P, Utz PJ. Human autoimmune sera as molecular probes for the identification of an autoantigen kinase signaling pathway. *J Exp Med* 2002; 196: 1213-25.
 105. Neugebauer KM, Merrill JT, Wener MH, Lahita RG, Roth MB. SR proteins are autoantigens in patients with systemic lupus erythematosus. Importance of phosphoepitopes. *Arthr Rheum* 2000; 43: 1768-78.
 106. Overzet K, Gensler TJ, Kim SJ, Geiger ME, van Venrooij WJ, Pollard KM, et al. Small nucleolar RNP scleroderma autoantigens associate with phosphorylated serine/arginine splicing factors during apoptosis. *Arthritis Rheum* 2000; 43: 1327-36.
 107. Utz PJ, Hottelet M, Schur PH, Anderson P. Proteins phosphorylated during stress-induced apoptosis are common targets for autoantibody production in patients with systemic lupus erythematosus. *J Exp Med* 1997; 185: 843-54.
 108. Fritzler MJ, Hamel JC, Ochs RL, Chan EKL. Molecular characterization of two human autoantigens: unique cDNAs encoding 95- and 160-kD proteins of a putative family in the Golgi complex. *J Exp Med* 1993; 178: 49-62.
 109. Fritzler MJ, Lung CC, Hamel JC, Griffith K, Chan EKL. Molecular characterization of Golgin-245, a novel Golgi complex protein containing a granin signature. *J Biol Chem* 1995; 270: 31262-8.
 110. Nozawa K, Fritzler MJ, von Muhlen CA, Chan EK. Giantin is the major Golgi autoantigen in human anti-Golgi complex sera. *Arthritis Res Ther* 2004; 6: R95-102.
 111. Cha H, Smith BL, Gallo K, Machamer CE, Shapiro P. Phosphorylation of golgin-160 by mixed lineage kinase 3. *J Cell Sci* 2004; 117: 751-60.
 112. Rutjes SA, Utz PJ, van der Heijden A, Broekhuis C, van Venrooij WJ, Pruijn GJ. The La (SS-B) autoantigen, a key protein in RNA biogenesis, is dephosphorylated and cleaved early during apoptosis. *Cell Death Differ* 1999; 6: 976-86.
 113. Utz PJ, Gensler TJ, Anderson P. Death, autoantigen modifications, and tolerance. *Arthritis Res* 2000; 2: 101-14.
 114. Zampieri S, Degen W, Ghiradello A, Doria A, van Venrooij WJ. Dephosphorylation of autoantigenic ribosomal P proteins during Fas-L induced apoptosis: a possible trigger for the development of the autoimmune response in patients with systemic lupus erythematosus. *Ann Rheum Dis* 2001; 60: 72-6.
 115. Uetrecht J. Current trends in drug-induced autoimmunity. *Autoimmun Rev* 2005; 4: 309-14.
 116. Atzeni F, Marrazza MG, Sarzi-Puttini P, Carrabba M, Atzeni F. Drug-induced lupus erythematosus. *Reumatismo* 2003; 55: 147-54.

117. Alarcon-Segovia D, Wakim KG, Worthington JW, Ward LE. Clinical and experimental studies on the hydralazine syndrome and its relationship to systemic lupus erythematosus. *Medicine (Baltimore)* 1967; 46: 1-33.
118. Ablin J, Verbovetski I, Trahtemberg U, Metzger S, Mevorach D. Quinidine and procainamide inhibit murine macrophage uptake of apoptotic and necrotic cells: a novel contributing mechanism of drug-induced-lupus. *Apoptosis* 2005; 10: 1009-18.
119. Lu Q, Wu A, Richardson BC. Demethylation of the same promoter sequence increases CD70 expression in lupus T cells and T cells treated with lupus-inducing drugs. *J Immunol* 2005; 174: 6212-9.
120. Alarcon-Segovia D, Fishbein E. Patterns of antinuclear antibodies and lupus-activating drugs. *J Rheumatol* 1975; 2: 167-71.
121. Vazquez-Del-Mercado M, Casiano CA, Rubin RL. IgA antihistone antibodies in isoniazid-treated tuberculosis patients. *Autoimmunity* 1995; 20: 105-11.
122. Smith CA, Wadelius M, Gough AC, Harrison DJ, Wolf CR, Rane A. A simplified assay for the arylamine N-acetyltransferase 2 polymorphism validated by phenotyping with isoniazid. *J Med Genet* 1997; 34: 758-60.
123. Nordstrom DM, West SG, Rubin RL. Methyl dopa-induced systemic lupus erythematosus. *Arthritis Rheum* 1989; 32: 205-8.
124. Homberg JC. Drug-induced autoimmune hemolytic anemia. *Presse Med* 1999; 28: 703-8.
125. Richardson B, Ray D, Yung R. Murine models of lupus induced by hypomethylated T cells. *Methods Mol Med* 2004; 102: 285-94.
126. Baeza I, Leyva E, Campos B, Lara M, Ibanez M, Falfan N, et al. Antibodies to non-bilayer phospholipid arrangements induce a murine autoimmune disease resembling human lupus. *Eur J Immunol* 2004; 34: 576-86.
127. Hieronymus T, Grotzsch P, Blank N, Grunke M, Capraru D, Geiler T, et al. Chlorpromazine induces apoptosis in activated human lymphoblasts: a mechanism supporting the induction of drug-induced lupus erythematosus? *Arthritis Rheum* 2000; 43: 1994-2004.
128. Schett G, Rubin RL, Steiner G, Hiesberger H, Muller S, Smolen J. The lupus erythematosus cell phenomenon: comparative analysis of antichromatin antibody specificity in lupus erythematosus cell-positive and -negative sera. *Arthritis Rheum* 2000; 43: 420-8.
129. Gunnarsson I, Nordmark B, Hassan-Bakri A, Grondal G, Larsson P, Forslid J, et al. Development of lupus-related side-effects in patients with early RA during sulphasalazine treatment-the role of IL-10 and HLA. *Rheumatology (Oxford)* 2000; 39: 886-93.
130. Furet Y, Bechtel Y, Le Guellec C, Bechtel PR, Autret-Leca E, Paintaud G. Clinical relevance of N-acetyltransferase type 2 (NAT2) genetic polymorphism. *Therapie* 2002; 57: 427-31.
131. Jain KK. Systemic lupus erythematosus (SLE)-like syndromes associated with carbamazepine therapy. *Drug Saf* 1991; 6: 350-60.
132. Furst SM, Uetrecht JP. The effect of carbamazepine and its reactive metabolite, 9-acridine carboxaldehyde, on immune cell function in vitro. *Int J Immunopharmacol* 1995; 17: 445-52.
133. Mizutani T, Shinoda M, Tanaka Y, Kuno T, Hattori A, Usui T, et al. Autoantibodies against CYP2D6 and other drug-metabolizing enzymes in autoimmune hepatitis type 2. *Drug Metab Rev* 2005; 37: 235-52.
134. Scheinfeld N. Impact of phenytoin therapy on the skin and skin disease. *Expert Opin Drug Saf* 2004; 3: 655-65.
135. Villasenor-Garcia MM, Puebla-Perez AM, Sandoval-Ramirez L, Lozoya X. Phenytoin and electric shock-induced apoptosis in rat peripheral blood lymphocytes. *Int J Immunopharmacol* 2000; 22: 143-50.
136. Salek FS, Bigos KL, Kroboth PD. The influence of hormones and pharmaceutical agents on DHEA and DHEA-S concentrations: a review of clinical studies. *J Clin Pharmacol* 2002; 42: 247-66.
137. Wiik A. Clinical and laboratory characteristics of drug-induced vasculitic syndromes. *Arthritis Res Ther* 2005; 7: 191-2.
138. Tamura M, Kimura H, Koji T, Tominaga T, Ashizawa K, Kiriya T, et al. Role of apoptosis of thyrocytes in a rat model of goiter. A possible involvement of Fas system. *Endocrinology* 1998; 139: 3646-53.
139. Seguin B, Boutros PC, Li X, Okey AB, Uetrecht JP. Gene expression profiling in a model of D-penicillamine-induced autoimmunity in the Brown Norway rat: predictive value of early signs of danger. *Chem Res Toxicol* 2005; 18: 1193-202.
140. Srivastava M, Rencic A, Diglio G, Santana H, Bonitz P, Watson R, et al. Drug-induced, Ro/SSA-positive cutaneous lupus erythematosus. *Arch Dermatol* 2003; 139: 45-9.
141. Querin S, Feuillet-Fieux MN, Jacob L, Niel G, Bach JF. Specificity of acebutolol-induced antinuclear antibodies. *J Immunopharmacol* 1986; 8: 633-49.
142. Wilson JD. Antinuclear antibodies and cardiovascular drugs. *Drugs* 1980; 19: 292-305.
143. Bonnet F, Morlat P, de Witte S, Combe C, Beylot J. Lupus-like syndrome and vasculitis induced by valpromide. *J Rheumatol* 2003; 30: 208-9.
144. Asconape JJ, Manning KR, Lancman ME. Systemic lupus erythematosus associated with use of valproate. *Epilepsia* 1994; 35: 162-3.
145. McKay DA, Schofield OM, Benton EC. Terbinafine-induced subacute cutaneous lupus erythematosus. *Acta Derm Venereol* 2004; 84: 472-4.
146. Bonsmann G, Schiller M, Luger TA, Stander S. Terbinafine-induced subacute cutaneous lupus erythematosus. *J Am Acad Dermatol* 2001; 44: 925-31.
147. Arnett FC, Fritzler MJ, Ahn C, Holian A. Urinary mercury levels in patients with autoantibodies to U3-RNP (fibrillarin). *J Rheumatol* 2000; 27: 405-10.
148. Pacheco FJ, Servin J, Dang D, Kim J, Molinaro C,

- Daniels T, et al. Involvement of lysosomal cathepsins in the cleavage of DNA topoisomerase I during necrotic cell death. *Arthritis Rheum* 2005; 52: 2133-5.
149. Herrera-vanOostdam DA, Esparza-Ibarra E, Ramirez-Sandoval R, Ortiz V, Bollain-y-Goitia JJ, Avalos-Diaz E, et al. Apoptosis and necrosis increase antigenicity of proteins recognized by antinuclear antibodies. *Reumatismo* 2004; 56: 156-61.
150. Herrera-Esparza R, Villalobos R, Bollain-Y-Goytia JJ, Ramirez-Sandoval R, Sanchez-Rodriguez SH, Pacheco-Tovar G, et al. Apoptosis and redistribution of the Ro autoantigen in Balb/c mouse like in subacute cutaneous lupus erythematosus. *Clin Dev Immunol*. 2006;13:163-6.
151. Liebes L, Potmesil M, Kim T, Pease D, Buckley M, Fry D, et al. Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan. *Clin Cancer Res* 1998; 4: 545-57.
152. Ayukawa K, Taniguchi S, Masumoto J, Hashimoto S, Sarvotham H, Hara A, et al. La autoantigen is cleaved in the COOH terminus and loses the nuclear localization signal during apoptosis. *J Biol Chem* 2000; 275: 34465-70.